Nuvalent (NUVL) surges on announced $10.6B all-cash acquisition

Nuvalent, Inc. (NUVL) is up 38.8% today. Here is some analysis on what might have caused this price movement.

Analysis: Nuvalent shares are jumping after the company announced it will be acquired in an all-cash deal, which typically pulls the target’s stock toward the stated offer price. The magnitude of the move suggests the market is rapidly repricing NUVL to reflect the takeover premium and the increased certainty of value realization versus standalone biotech development risk.

Details:

Nuvalent disclosed a definitive acquisition agreement for an all-cash transaction valuing the company at about $10.6 billion.

The announced consideration is $124 per share in cash, implying a sizable premium to Nuvalent’s prior close and helping explain the sharp gap-up in the stock.

The acquirer highlighted Nuvalent’s pipeline of targeted oncology candidates, including programs aimed at genetically defined lung cancer populations.

Separately, Nuvalent has recently communicated ongoing clinical and regulatory progress across its lead assets, which may have supported deal interest and investor confidence into the announcement.

Sources:

GSK, Investing.com, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NUVL Insider Trading Activity

$NUVL insiders have traded $NUVL stock on the open market 102 times in the past 6 months. Of those trades, 0 have been purchases and 102 have been sales.

Here’s a breakdown of recent trading of $NUVL stock by insiders over the last 6 months:

JAMES RICHARD PORTER (President and CEO) has made 0 purchases and 16 sales selling 87,433 shares for an estimated $8,832,202.
ALEXANDRA BALCOM (Chief Financial Officer) has made 0 purchases and 17 sales selling 55,407 shares for an estimated $5,522,057.
DEBORAH ANN MILLER (Chief Legal Officer) has made 0 purchases and 21 sales selling 43,952 shares for an estimated $4,576,904.
HENRY E. PELISH (Chief Scientific Officer) has made 0 purchases and 15 sales selling 43,357 shares for an estimated $4,267,773.
DARLENE NOCI (Chief Development Officer) has made 0 purchases and 26 sales selling 38,917 shares for an estimated $3,927,992.
CHRISTOPHER DURANT TURNER (Chief Medical Officer) has made 0 purchases and 7 sales selling 7,417 shares for an estimated $721,320.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive NUVL Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NUVL Hedge Fund Activity

We have seen 162 institutional investors add shares of $NUVL stock to their portfolio, and 102 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 1,577,925 shares (-14.5%) from their portfolio in Q1 2026, for an estimated $161,248,155
DEEP TRACK CAPITAL, LP added 1,376,324 shares (+inf%) to their portfolio in Q1 2026, for an estimated $140,646,549
DEERFIELD MANAGEMENT COMPANY, L.P. removed 742,574 shares (-4.1%) from their portfolio in Q4 2025, for an estimated $74,695,518
FAIRMOUNT FUNDS MANAGEMENT LLC removed 727,563 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $74,349,662
JANUS HENDERSON GROUP PLC removed 689,100 shares (-31.5%) from their portfolio in Q4 2025, for an estimated $69,316,569
RA CAPITAL MANAGEMENT, L.P. added 654,088 shares (+34.8%) to their portfolio in Q1 2026, for an estimated $66,841,252
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 652,462 shares (-63.9%) from their portfolio in Q4 2025, for an estimated $65,631,152

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NUVL Analyst Ratings

Wall Street analysts have issued reports on $NUVL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 12/19/2025

To track analyst ratings and price targets for $NUVL, check out Quiver Quantitative's $NUVL forecast page.

$NUVL Price Targets

Multiple analysts have issued price targets for $NUVL recently. We have seen 7 analysts offer price targets for $NUVL in the last 6 months, with a median target of $140.0.

Here are some recent targets:

David Nierengarten from Wedbush set a target price of $124.0 on 06/09/2026
An analyst from LifeSci Capital set a target price of $124.0 on 06/09/2026
Jeffrey Walch from Bernstein set a target price of $189.0 on 05/22/2026
Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $155.0 on 04/21/2026
Eva Fortea Verdejo from Wells Fargo set a target price of $116.0 on 03/30/2026
Josh Schimmer from Cantor Fitzgerald set a target price of $140.0 on 02/27/2026
Anupam Rama from JP Morgan set a target price of $145.0 on 12/19/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.